Twist Bioscience Corp (TWST) – SEC staff letter
2026-03-05 · Re: oration Form 10-K for Fiscal Year Ended September 30, 2025 · Accession 0000000000-26-002279 · Review completed (no further comments)
March 5, 2026 Adam Laponis Chief Financial Officer Twist Bioscience Corporation 681 Gateway Blvd South San Francisco, CA 94080 Re: Twist Bioscience Corporation Form 10-K for Fiscal Year Ended September 30, 2025 File No. 001-38720 Dear Adam Laponis: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Full letter on EDGAR → · Filing index · All Twist Bioscience Corp (TWST) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)